Atezolizumab as first line treatment in cisplatin ineligible patients with locally advanced and metastatic urothelial carcinoma: a single arm, multicentre, phase 2 trial
BACKGROUND First line chemotherapy for patients with cisplatin ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti programmed death ligand 1 [PD L1] as treatment for metastatic urothelial cancer in cisplatin ineligible patients. METHODS For this single arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review) assessed in prespecified subgroups based on PD L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652. FINDINGS Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17*2 months' median follow up, the objective response rate was 23% (95% CI 16 to 31) the complete response rate was 9% (n=11) and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD L1 and poor prognostic factor subgroups. Median progression free survival was 2*7 months (2*1 to 4*2) Median overall survival was 15*9 months (10*4 to not estimable) Tumour mutation load was associated with response. Treatment related adverse events that occurred in 10% or more of patients were fatigue (36 [30% patients) diarrhoea (14 [12% patients) and pruritus (13 [11% patients) One treatment related death (sepsis) occurred. Nine (8% patients had an adverse event leading to treatment discontinuation. Immune mediated events occurred in 14 (12% patients. INTERPRETATION Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer. FUNDING F Hoffmann La Roche, Genentech.
The Lancet